These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 23067780)
21. Family caregiver quality of life in multiple sclerosis among Kuwaitis: a controlled study. Alshubaili AF; Ohaeri JU; Awadalla AW; Mabrouk AA BMC Health Serv Res; 2008 Oct; 8():206. PubMed ID: 18840287 [TBL] [Abstract][Full Text] [Related]
22. Costs and quality of life of multiple sclerosis in Italy. Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336 [TBL] [Abstract][Full Text] [Related]
23. [A study of the quality of life in cases of multiple sclerosis]. Delgado-Mendilívar JM; Cadenas-Díaz JC; Fernández-Torrico JM; Navarro-Mascarell G; Izquierdo G Rev Neurol; 2005 Sep 1-15; 41(5):257-62. PubMed ID: 16138280 [TBL] [Abstract][Full Text] [Related]
24. Costs and quality of life for patients with multiple sclerosis in Belgium. Kobelt G Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662 [TBL] [Abstract][Full Text] [Related]
25. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status. Ostberg A; Pittas F; Taylor B Intern Med J; 2005 Jul; 35(7):382-7. PubMed ID: 15958106 [TBL] [Abstract][Full Text] [Related]
29. Cross-cultural adaptation and validation of multiple sclerosis quality of life questionnaire (MSQOL-54) in a Turkish multiple sclerosis sample. Idiman E; Uzunel F; Ozakbas S; Yozbatiran N; Oguz M; Callioglu B; Gokce N; Bahar Z J Neurol Sci; 2006 Jan; 240(1-2):77-80. PubMed ID: 16277993 [TBL] [Abstract][Full Text] [Related]
30. Quality of life in multiple sclerosis: a Kuwaiti MSQOL-54 experience. Alshubaili AF; Ohaeri JU; Awadalla AW; Mabrouk AA Acta Neurol Scand; 2008 Jun; 117(6):384-92. PubMed ID: 18028242 [TBL] [Abstract][Full Text] [Related]
31. Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time? Schwartz CE; Quaranto BR; Healy BC; Benedict RH; Vollmer TL Arch Phys Med Rehabil; 2013 Oct; 94(10):1971-81. PubMed ID: 23727344 [TBL] [Abstract][Full Text] [Related]
32. Influence of Interferon beta treatment on quality of life in multiple sclerosis patients. Simone IL; Ceccarelli A; Tortorella C; Bellacosa A; Pellegrini F; Plasmati I; De Caro MF; Lopez M; Girolamo F; Livrea P Health Qual Life Outcomes; 2006 Dec; 4():96. PubMed ID: 17163989 [TBL] [Abstract][Full Text] [Related]
33. A reassessment of the plateauing relationship between T2 lesion load and disability in MS. Sormani MP; Rovaris M; Comi G; Filippi M Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123 [TBL] [Abstract][Full Text] [Related]
34. Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS). Twiss J; Doward LC; McKenna SP; Eckert B Health Qual Life Outcomes; 2010 Oct; 8():117. PubMed ID: 20937112 [TBL] [Abstract][Full Text] [Related]
35. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. Ozakbas S; Cagiran I; Ormeci B; Idiman E J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626 [TBL] [Abstract][Full Text] [Related]
36. Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. Janardhan V; Bakshi R Arch Neurol; 2000 Oct; 57(10):1485-91. PubMed ID: 11030802 [TBL] [Abstract][Full Text] [Related]
37. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS? Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802 [TBL] [Abstract][Full Text] [Related]
38. A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study. Ziemssen T; Piani-Meier D; Bennett B; Johnson C; Tinsley K; Trigg A; Hach T; Dahlke F; Tomic D; Tolley C; Freedman MS J Med Internet Res; 2020 Feb; 22(2):e16932. PubMed ID: 32049062 [TBL] [Abstract][Full Text] [Related]
39. Fatigue in multiple sclerosis: relationship with disease duration, physical disability, disease pattern, age and sex. Ghajarzadeh M; Jalilian R; Eskandari G; Sahraian MA; Azimi A; Mohammadifar M Acta Neurol Belg; 2013 Dec; 113(4):411-4. PubMed ID: 23616230 [TBL] [Abstract][Full Text] [Related]
40. Difference between generic and multiple sclerosis-specific quality of life instruments regarding the assessment of treatment efficacy. Ozakbas S; Akdede BB; Kösehasanogullari G; Aksan O; Idiman E J Neurol Sci; 2007 May; 256(1-2):30-4. PubMed ID: 17379247 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]